Loading...
Statistics
Advertisement

KRF HP
www.krf-j.jp/

Krf-j.jp

Advertisement
Conversion Technology Metas Server
Krf-j.jp is hosted in Japan / Tokyo . Krf-j.jp doesn't use HTTPS protocol. Number of used technologies: 2. First technologies: CSS, Html, Number of used javascripts: 0. Number of used analytics tools: 0. Its server type is: Apache.

Technologies in use by Krf-j.jp

Technology

Number of occurences: 2
  • CSS
  • Html

Advertisement

Server Type

  • Apache

Conversion rate optimization
visitors Clickable call number Not founded!
visitors Conversion form (contact form, subcriber) Not founded!
visitors Clickable email Founded!
visitors CTA (call to action) button Not founded!
visitors List Not founded!
visitors Image Not founded!
visitors Enhancement Not founded!
visitors Responsive website Not founded!
visitors Facebook sharing Not founded!
visitors Google+ sharing Not founded!
visitors Twitter sharing Not founded!
visitors Linkedin sharing Not founded!
visitors Blog on the webiste Not founded!

HTTPS (SSL) - Krf-j.jp

Missing HTTPS protocol.

    Meta - Krf-j.jp

    Number of occurences: 2
    • Name: GENERATOR
      Content: @NetHomeホームページ作成ツール Ver.1.0.1.1 for Windows
    • Name:
      Content: text/html; charset=Shift_JIS

    Server / Hosting

    • IP: 157.7.107.145
    • Latitude: 35.69
    • Longitude: 139.75
    • Country: Japan
    • City: Tokyo

    Rname

    • uns01.lolipop.jp
    • uns02.lolipop.jp
    • mx01.lolipop.jp

    Target

    • admin.madame.jp

    HTTP Header Response

    HTTP/1.1 200 OK Date: Sun, 24 Jul 2016 12:25:51 GMT Server: Apache Last-Modified: Sat, 07 May 2016 03:29:52 GMT Accept-Ranges: bytes Content-Length: 24651 Vary: Accept-Encoding Content-Type: text/html X-Cache: MISS from s_sr109 X-Cache-Lookup: MISS from s_sr109:80 Via: 1.1 s_sr109 (squid/3.5.14) Connection: keep-alive

    DNS

    host: krf-j.jp
    1. class: IN
    2. ttl: 86400
    3. type: A
    4. ip: 157.7.107.145
    host: krf-j.jp
    1. class: IN
    2. ttl: 86400
    3. type: NS
    4. target: uns01.lolipop.jp
    host: krf-j.jp
    1. class: IN
    2. ttl: 86400
    3. type: NS
    4. target: uns02.lolipop.jp
    host: krf-j.jp
    1. class: IN
    2. ttl: 86400
    3. type: SOA
    4. mname: uns01.lolipop.jp
    5. rname: admin.madame.jp
    6. serial: 2011042421
    7. refresh: 60
    8. retry: 3600
    9. expire: 1209600
    10. minimum-ttl: 86400
    host: krf-j.jp
    1. class: IN
    2. ttl: 86400
    3. type: MX
    4. pri: 10
    5. target: mx01.lolipop.jp

    Common Typos/Mistakes

    This list shows You some spelling mistakes at internet search for this domain.

    www.rf-j.jp, www.ktrf-j.jp, www.trf-j.jp, www.krf-j.jp, www.rf-j.jp, www.kgrf-j.jp, www.grf-j.jp, www.kbrf-j.jp, www.brf-j.jp, www.knrf-j.jp, www.nrf-j.jp, www.khrf-j.jp, www.hrf-j.jp, www.kyrf-j.jp, www.yrf-j.jp, www.klrf-j.jp, www.lrf-j.jp, www.korf-j.jp, www.orf-j.jp, www.kurf-j.jp, www.urf-j.jp, www.kirf-j.jp, www.irf-j.jp, www.kmrf-j.jp, www.mrf-j.jp, www.kf-j.jp, www.krif-j.jp, www.kif-j.jp, www.krof-j.jp, www.kof-j.jp, www.krlf-j.jp, www.klf-j.jp, www.krlf-j.jp, www.klf-j.jp, www.kr.f-j.jp, www.k.f-j.jp, www.kr-j.jp, www.krfq-j.jp, www.krq-j.jp, www.krf-j.jp, www.kr-j.jp, www.krfa-j.jp, www.kra-j.jp, www.krfy-j.jp, www.kry-j.jp, www.krft-j.jp, www.krt-j.jp, www.krfg-j.jp, www.krg-j.jp, www.krfb-j.jp, www.krb-j.jp, www.krfw-j.jp, www.krw-j.jp, www.krfs-j.jp, www.krs-j.jp, www.krfd-j.jp, www.krd-j.jp, www.krfr-j.jp, www.krr-j.jp, www.krf3-j.jp, www.kr3-j.jp, www.krf4-j.jp, www.kr4-j.jp, www.krfj.jp, www.krf-tj.jp, www.krftj.jp, www.krf-gj.jp, www.krfgj.jp, www.krf-hj.jp, www.krfhj.jp, www.krf-uj.jp, www.krfuj.jp, www.krf-jj.jp, www.krfjj.jp, www.krf-xj.jp, www.krfxj.jp, www.krf-sj.jp, www.krfsj.jp, www.krf-aj.jp, www.krfaj.jp, www.krf-j.jp, www.krfj.jp, www.krf- j.jp, www.krf j.jp, www.krf-.jp, www.krf-jz.jp, www.krf-z.jp, www.krf-jh.jp, www.krf-h.jp, www.krf-jn.jp, www.krf-n.jp, www.krf-j..jp, www.krf-..jp, www.krf-ju.jp, www.krf-u.jp, www.krf-jk.jp, www.krf-k.jp, www.krf-jl.jp, www.krf-l.jp, www.krf-jo.jp, www.krf-o.jp,

    Other websites we recently analyzed

    1. dollarhustler.com
      Provo (United States) - 50.87.248.203
      Server software: nginx/1.10.0
      Technology: CSS, Html, Html5, jQuery, Wordpress
      Number of Javascript: 4
      Number of meta tags: 2
    2. ** INDHU ** Instituto Nacional de Desarrollo Humano
      Scottsdale (United States) - 68.178.254.120
      Server software: Apache
      Technology: Html, Javascript, Swf Object
      Number of Javascript: 2
      Number of meta tags: 1
    3. Search Results for "kolotibalo.com"
      El Segundo (United States) - 208.87.150.50
      Server software: Microsoft-IIS/8.5
      Technology: CSS, Html, Javascript
      Number of meta tags: 1
    4. apartamentos para mayores
      apartamentos para mayores de 65 años
      Ashburn (United States) - 54.85.150.195
      Server software: nginx
      Technology: CSS, Html, Html5, Javascript, Wix
      Number of Javascript: 2
      Number of meta tags: 8
    5. Домен не прилинкован ни к одному сайту! Хостинг-провайдер BeGet.ru
      Russian Federation - 5.101.152.115
      Server software: nginx-reuseport/1.10.0
      Technology: CSS, Html, Html5
      Number of meta tags: 1
    6. Главная
      Ukraine - 91.222.136.153
      Server software: nginx
      Technology: Carousel, CSS, Html, Html5, Javascript, LiveInternet counter
      Number of Javascript: 11
      Number of meta tags: 3
    7. WSB S.A.
      Rosario (Argentina) - 200.58.111.135
      Server software: nginx
      Technology: CSS, Html, Javascript, Php
      Number of Javascript: 2
      Number of meta tags: 1
    8. MARMARA TEKNiK Modüler Busbar Sistemleri
      elektrik,enerji,busbar
      Turkey - 94.73.144.100
      Server software: Microsoft-IIS/6.0
      Technology: CSS, Html, Javascript
      Number of meta tags: 5
    9. Home
      Burlington (United States) - 65.254.248.196
      Server software: Apache/2
      Technology: CSS, Html, Javascript
      Number of Javascript: 2
      Number of meta tags: 2
    10. Rituxan® (rituximab) GPA and MPA Treatment
      Learn about Rituxan® (rituximab), used for Granulomatosis with Polyangiitis (formerly Wegener's Granulomatosis) and Microscopic Polyangiitis treatment. Rituxan® (Rituximab) is indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent, Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy, Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy, Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens, Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rituxan is not recommended for use in patients with severe, active infections. BOXED WARNINGS: Rituxan administration can result in serious, including fatal, adverse reactions. These include infusion reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. BOXED WARNINGS: WARNING: FATAL INFUSION REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY. Infusion Reactions: Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving Rituxan [see Warnings and Precautions. WARNINGS AND PRECAUTIONS: Tumor Lysis Syndrome: Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of Rituxan in patients with NHL. Infections: Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of Rituxan-based therapy. Cardiovascular: Discontinue infusions for serious or life‑threatening cardiac arrhythmias. Renal: Severe, including fatal, renal toxicity can occur after Rituxan administration in patients with NHL. Bowel Obstruction and Perforation: Abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving Rituxan in combination with chemotherapy. ADDITIONAL IMPORTANT SAFETY INFORMATION: The most common Grade 3 or 4 adverse reactions in clinical trials of NHL and CLL were infusion reactions, neutropenia, leukopenia, anemia, thrombocytopenia, and infections. Additionally, lymphopenia and lung disorder were seen in NHL trials; and febrile neutropenia, pancytopenia, hypotension, and hepatitis B were seen in CLL trials. The most common adverse reactions (incidence ≥25%) in clinical trials of NHL and CLL were infusion reactions. Additionally, fever, lymphopenia, chills, infection, and asthenia were seen in NHL trials; and neutropenia was seen in CLL trials. For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide. Attention Healthcare Provider: Provide Medication Guide to patient prior to Rituxan infusion. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
      San Jose (United States) - 52.9.248.182
      G Analytics ID: UA-48965244-1
      Server software: BigIP
      Technology: CSS, Html, Javascript, Google Analytics, Optimizely, Share This Social Media Buttons
      Number of Javascript: 13
      Number of meta tags: 4

    Check Other Websites